Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-04-2007 | editorial

Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders?

Auteurs: A. A. M. Wilde, P. Langendijk

Gepubliceerd in: Netherlands Heart Journal | Uitgave 4/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Antiarrhythmic drugs no longer seem to be big business. After the unexpected CAST trial results (excess mortality in the class 1C antiarrhythmic drug treatment arms in patients with coronary artery disease (CAD) and abundant ventricular extrasystoles),1 antiarrhythmic drug treatment became less popular for CAD patients. Since this category of patients represents the majority of cardiology patients with chronic disease, these results impacted on the antiarrhythmic drug market. In the years that followed, the use of class 1C drugs was even further discouraged.
volgende artikel Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation?
Literatuur
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-24.
Dorian P, Borggreve M, Al-Khalidi, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110:3646-54.
Jongman J, Jepkes-Bruin N, Ramdat Misier AR, Beukema WP, Delnoy PPHM, Oude Luttikhuis H, et al. Electrical storms in Brugada syndrome successfully treated with isoprenaline infusion and quinidine orally. Neth Heart J 2007,15:151-4.
Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731-7.
Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999;20:465-70.
Metagegevens
Titel
Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders?
Auteurs
A. A. M. Wilde
P. Langendijk
Publicatiedatum
01-04-2007
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 4/2007
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03085967

Andere artikelen Uitgave 4/2007

Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation?

  • original article

Exercise prescription for patients with a Fontan circulation: current evidence and future directions

  • review article

Crossing coronary arteries

  • imaging in cardiology

Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy

  • special article

Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally

  • case report

Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study

  • original article